Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs BMS 986235 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Mar 2018 Planned End Date changed from 15 Jul 2018 to 23 Sep 2018.
- 27 Mar 2018 Planned primary completion date changed from 12 Jul 2018 to 23 Sep 2018.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.